Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

257.30$25.29 10.90%
At close       04:00 PM   

Stock Snapshot

232.01
Prev. Close
234.24
Open
19.14B
Market Cap
5.89M
Number of Shares
233.54
Day Low
260.69
Day High
257.30
-
P/E Ratio
74.07M
Free Float in %
-13.84
EPS 2021
10.06
Book Value per Share
27.89
Cash Flow per Share
Novavax, Inc. (NVAX)
Novavax, Inc. (NVAX) stock rallied over 10.90% intraday to trade at $257.30 share on NASDAQ. The stock opened with a gain of % at $234.24 and touched an intraday high of $260.69, rising 12.36% against the last close of $232.01. The stock went to a low of $233.54 during the session.

Historical Data

DateOpenCloseDaily HighDaily LowVolume
2021-09-10$247.34$242.18$253.36$240.255,195,647
2021-09-03$254.00$251.49$255.48$242.55431,660,000
2021-09-02$252.44$258.99$261.48$251.01335,780,000
2021-09-01$238.00$252.06$258.77$235.11612,490,000
2021-08-31$235.00$238.54$244.90$232.20407,480,000
2021-08-30$224.31$233.23$238.20$223.10268,500,000
2021-08-27$230.83$226.67$231.47$222.10289,770,000
2021-08-26$238.18$230.34$242.56$227.45269,300,000
2021-08-25$229.20$238.18$245.87$228.51374,370,000
2021-08-24$243.14$233.01$243.14$228.02581,500,000
2021-08-23$236.00$251.00$251.13$231.08481,810,000
Novavax, Inc.
21 Firstfield Road
Gaithersburg, MD 20878
United States

http://www.novavax.com
240 268 2000
Employees
791
Sector
Healthcare
Sales or Revenue
1.18B
Industry
Biotechnology
5Y Sales Change
67.30
Fiscal Year Ends
2020-12-30

Novavax, Inc.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam